Document:

EX-10.4

 Exhibit 10.4 

  
 Portions herein identified by
[*****] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange
Commission. 
  

					
	S08-216 · GWK	  	Amendment	  	7/29/2018

  

 AMENDMENT No 2 

TO THE 
 LICENSE AGREEMENT
EFFECTIVE THE 25TH DAY OF JANUARY 2012 
 BETWEEN 

STANFORD UNIVERSITY 
 AND

 RUGA CORPORATION 
 Effective the
29th day of June 2015, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ruga Corporation (“Ruga”), a
corporation having a principal place of business at One Market Plaza - Spear Tower, Suite 3600, San Francisco, CA 94105 agree as follows: 
  

	1.	 BACKGROUND 

Stanford and Ruga are parties to a license agreement effective the 25th day of January 2015 (“Original Agreement”) covering “Biologic
inhibitors for therapeutic targeting the receptor tyrosine kinase AXL” disclosed in Stanford docket S08-216. 
 Stanford and Ruga wish to amend the
Original Agreement to among other things amend certain provisions with respect to sublicenses and include additional patents from the following inventions: “Inhibition of AXL/GAS6 signaling in the treatment of disease” (docket S08-216B),
“Inhibition of AXL signaling in primary tumor therapy” (docket S08-216C), and “Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy” (S08-216D), and High-Affinity Binding to Gas6
(S13-365). 
  

	2.	 AMENDMENT 

BACKGROUND of Original Agreement is hereby amended as follows: 

Stanford has assignments of inventions for cancer treatment and compounds that are active against for treatment of cancer. These were invented
in the laboratory of Drs. Jennifer Cochran and Amato Giaccia: “Biologic inhibitors for therapeutic targeting the receptor tyrosine kinase AXL” (docket S08-216), “Inhibition of AXL/GAS6 signaling in the treatment of disease”
(docket S08-216B), “Inhibition of AXL signaling in primary tumor therapy” (docket S08-216C), and “Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic 

  
 Page 1 of 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

 

					
	S08-216 · GWK	  	Amendment	  	7/29/2018

  

 
therapy” (S08-216D), High-Affinity Binding to Gas6 (S13-365). Stanford’s inventions S08-216 and S08-216B were made in the course of research supported by the Coulter Foundation.
Stanford wants to have these inventions perfected and marketed as soon as possible so that resulting products may be available for public use and benefit. 

Paragraph 2.2 of Original Agreement is hereby deleted and replaced with the following: 

“Exclusive Licensed Field of Use” means the treatment, prevention, palliation, or diagnosis of diseases, conditions, syndromes, and
maladies of humans and animals. 
 Paragraph 2.8 of Original Agreement is hereby deleted in its entirety. 

Paragraph 2.4 of Original Agreement is hereby amended as follows: 

“Jointly Owned Patents” means Serial Number PCT/US2013/074786, filed December 12, 2013; Serial Number 14/650,854, filed
December 12, 2013; Serial Number PCT/US2012/069841, filed December 14, 2012; Serial Number 13/714,875, filed December 14, 2012; (a) any and all U.S. Patent Applications related or derived from Solely Owned Patents as defined
below that name as inventors at least one inventor who is named as an inventor in a Solely Owned Patent and is obligated to assign his/her rights in such invention to RUGA; (b) any and all foreign patent applications corresponding thereto for
any of these patent applications defined herein; (c) any and all patents that issue from any of these patent applications defined herein; and (d) any and all reissues, reexaminations or foreign equivalents thereof of any of these patents
defined herein. 
 Paragraph 2.5 of Original Agreement is hereby amended as follows: 

“Solely Owned Patents” mean Stanford’s U.S. Patent Applications, Serial Number 61/336,478, filed January 22, 2010; Serial
Number 61/872,602, filed on August 30, 2013; Serial Number PCT/US2013/074809, filed December 12, 2013; Serial Number 14/650,852, filed December 12, 2013; Serial Number US2013/074796, filed on December 12, 2013; any patent
applications corresponding thereto, and any divisional, continuation, continuation-in-part filed within two (2) years of the Effective Date (and any foreign application corresponding thereto) that is supported by the specification of the parent
application, or reexamination application, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired issued Licensed Patent is presumed to be valid unless it has been held to be invalid by a final
judgment of a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part (CIP) patent application or patent initially filed more than two (2) years of the Effective
Date. 
 Paragraph 4.3 (B) of Original Agreement is hereby deleted and replaced with the following: 

“(B) will reflect that any sublicense shall have the unrestricted right to sublicense through multiple tiers to any third parties
provided that Stanford’s rights are not compromised.” 

  
 Page 2 of 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

 

					
	S08-216 · GWK	  	Amendment	  	7/29/2015

  

 Paragraph 4.6 of Original Agreement is hereby amended by the addition of the following sentence at the end:

 “It is acknowledged and agreed that this Section 4.6 only applies to Ruga, and not sublicenses.” 

Appendix A shall be amended by the addition of the following sentence at the end: 

“Provided there is reasonable regulatory/clinical justification. Ruga may extend Milestones 9, 10, 11 by up to an additional twenty four
(24) months upon written notice to Stanford.” 
 Appendix B shall be added to License with an updated list of all patents included in the
license (whether solely or jointly owned).” 
  

	3.	 OTHER TERMS 

  

	3.1	 All other terms of the Original Agreement remain in full force and effect. 

 

	3.2	 The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original
signature. 

  
 Page 3 of 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

 

					
	S08-216 · GWK	  	Amendment	  	7/29/2015

  

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No 2 in duplicate originals by their duly
authorized officers or representatives. 
  

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature:	 	 /s/ Katharine Ku

	Name:	 	 Katharine Ku

	Title:	 	 Executive Director

	Date:	 	 August 14, 2015

  

			
	RUGA CORPORATION
		
	Signature:	 	 /s/ Raymond Tabibiazar

	Name:	 	 Raymond Tabibiazar

	Title:	 	 CEO

	Date:	 	 7/29/2015

  
 Page 4 of 5 

 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

 

					
	S08-216 · GWK	  	Amendment	  	7/29/2015

  

 Appendix B- 

[*****] 

  
 Page 5 of 5EX-10.5

 Exhibit 10.5 

PORTIONS HEREIN IDENTIFIED BY [*****] HAVE BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF
THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. A COMPLETE COPY OF THIS
DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 EXECUTION COPY 
 S08-216 ·
CM/xa 
  

					
		  	AMENDMENT	  	09/25/2017

  

AMENDMENT No 3 
 TO THE

 LICENSE AGREEMENT EFFECTIVE THE 25TH DAY OF JANUARY 2012 

BETWEEN 
 STANFORD
UNIVERSITY 
 AND 

ARAVIVE BIOLOGICS, INC. (f/k/a RUGA CORPORATION) 

Effective the 15th day of September, 2017, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
(“Stanford”), an institution of higher education having powers under the laws of the State of California, and ARAVIVE BIOLOGICS, INC. (“Aravive”), a corporation having a principal place of business at 1221 McKinney, Ste. 3200,
Houston, Texas 77010, agree as follows: 
  

	1.	 BACKGROUND 

  

	1.1	 Stanford and Aravive are parties to a License Agreement effective the 25th day of January 2012 (“Original
Agreement”) covering “Biologic inhibitors for therapeutic targeting the receptor tyrosine kinase AXL” disclosed in Stanford Docket S08-216, from the laboratory of Dr. Amato Giaccia.

  

	1.2	 The Original Agreement was put in place between Stanford and Ruga Corporation (“Ruga”). Ruga
officially changed its name to Aravive Biologics, Inc. in November of 2016. 

  

	1.3	 The Original Agreement was amended by an Amendment No. 1 effective July 26, 2012 (“Amended
Original Agreement”). 

  

	1.4	 The Amended Original Agreement was further amended by an Amendment No. 2 effective June 29, 2015
(“Twice-Amended Original Agreement”). 

  

	1.5	 Stanford and Aravive wish to amend the Twice-Amended Original Agreement in order to modify Appendix A, and to
include additional patents from the following inventions: “Treating Fibrosis by Inhibiting AXL/Gas6 Signaling” (Docket S15-013). 

  
  

PAGE 1 OF 4 

 PORTIONS HEREIN IDENTIFIED BY [*****]
HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER
RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. A COMPLETE COPY
OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 EXECUTION COPY 

S08-216 · CM/xa 
  

					
		  	AMENDMENT	  	09/25/2017

  
  

	2.	 AMENDMENT 

  

	2.1	 Paragraph 2.4 of the Twice-Amended Original Agreement is hereby deleted in its entirety and replaced with the
following: 

 “Jointly Owned Patents” means each of (I) Serial Number PCT/US2012/069841, filed
December 14, 2012; Serial Number 13/714,875, filed December 14, 2012 ; Serial Number PCT/US2013/074786, filed December 12, 2013; Serial Number 14/650,854, filed June 9, 2015; Serial Number PCT/US2015/066498, filed
December 17, 2015; Serial Number 15/535,995, filed June 14, 2017; and (II)(a) any and all U.S. Patent Applications related or derived from Solely Owned Patents as defined below that name as inventors at least one inventor who is named as
an inventor on a Solely Owned Patent and is obligated to assign his/her rights in such invention to Aravive; (b) any and all foreign patent applications corresponding thereto for any of these patent applications defined herein; (c) any and
all patents that issue from any of these patent applications defined herein; and (d) any and all reissues, reexaminations or foreign equivalents thereof of any of these patents defined herein. 

 

	2.2	 Paragraph 2.5 of the Twice-Amended Original Agreement is hereby deleted in its entirety and replaced with the
following: 

  

	2.3	 “Solely Owned Patents” means Stanford’s U.S. Patent Applications, Serial Number
PCT/US2011/022125, filed January 21, 2011; Serial Number 13/554,954, filedJuly 20, 2012; Serial Number 13/595,936, filed August 27, 2012; Serial Number 13/950,111, filed July 24, 2013; Serial Number 14/712,731, filed May 14,
2015; Serial Number PCT/US2013/074809, filed December 12, 2013; Serial Number 14/650,852, filed June 9, 2015; Serial Number PCT/US2013/074796, filed December 12, 2013; Serial Number 14/910,565, filed February 5, 2016; any patent
applications corresponding thereto, and any divisional, continuation, or reexamination application, and each patent that issues or reissues from any of these patent applications. “Licensed Patent” includes continuation-in-part (“CIP”) patent applications or patents that issues and reissues from a patent application but only to the extent they cover technology fully supported by the specification of
the parent application. The CIP applications expressly do not include CIP applications that are the result of sponsored research or any other agreement between Stanford and a third party pursuant to which such third party has rights to such
invention. Any claim of an unexpired issued Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. 

 

	2.4	 Appendix A of the Amended Original Agreement is amended by adding the following sentence at the end of the last
paragraph in Appendix A: 

 In addition, Aravive may extend milestones 5-11 for an additional 2
years for Licensed Products that read under Licensed Patents filed after December 1st, 2014 which were not previously included in the Original Agreement; however, for each such Licensed Product
the “year” references shall be to effective date of this Amendment No 3 so for example “year 2” is the second anniversary of the effective date of this Amendment No 3. 

  
  

PAGE 2 OF 4 

 PORTIONS HEREIN IDENTIFIED BY [*****]
HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER
RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. A COMPLETE COPY
OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 EXECUTION COPY 

S08-216 · CM/xa 
  

					
		  	AMENDMENT	  	09/25/2017

  
  

	2.5	 Appendix B that was annexed to the Twice-Amended Original Agreement is replaced with Appendix B annexed hereto,
which sets forth a list of all Licensed Patents included in the License. 

  

	2.6	 Section 7.3 of the Original Agreement is amended by adding the following sentence at the end of the
section: 

 The milestone payments shall be due only once and solely for the first Licensed Product to reach each
applicable milestone, subject solely to the additional payment set forth below: 
 In consideration for the addition of the fibrosis docket
(Serial Number 15/535,995, filed June 14, 2017), $[****] approval of the first NDA/BLA or equivalent in a Major Market to treat Fibrosis, provided that (1) it is follow-on regulatory approval for an
already-approved Licensed Product, (2) it results from a separate and dedicated clinical study, and (3) treatment of fibrosis is explicitly specified on the label. 
  

	3.	 OTHER TERMS 

  

	3.1	 It is hereby acknowledged that the Original Agreement is clear that revenue from the sale of a Licensed Product
triggers the earned royalty pursuant to Section 7 and the royalty rate does not increase regardless of the number of Licensed Patents which would be infringed in the country of sale by making, having made, using, or offer for sale, selling or
importing the Licensed Product (i.e. the number of Licensed Patents that a Licensed Product infringes has no impact on the royalty rate). 

  

	3.2	 All other terms of the Twice-Amended Original Agreement remain in full force and effect. 

 

	3.3	 The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original
signature. 

  
  

PAGE 3 OF 4 

 PORTIONS HEREIN IDENTIFIED BY [*****]
HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER
RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. A COMPLETE COPY
OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 EXECUTION COPY 

S08-216 · CM/xa 
  

					
		  	AMENDMENT	  	09/25/2017

  
  

 The parties execute this Amendment No 3 by their duly authorized officers or representatives. 

 

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature:	 	 /s/ Mona Wan

	Name:	 	 Mona Wan

	Title:	 	 Associate Director

	Date:	 	 Oct. 2, 2017

	
	ARAVIVE BIOLOGICS, INC.
		
	Signature:	 	 /s/ Ray Tabibiazar

	Name:	 	 Ray Tabibiazar

	Title:	 	 Chairman

	Date:	 	 09-27-2017

  
  

PAGE 4 OF 4 

 PORTIONS HEREIN IDENTIFIED BY [*****]
HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER
RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. A COMPLETE COPY
OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 EXECUTION COPY 

S08-216 · CM/xa 
  

					
		  	AMENDMENT	  	09/25/2017

  
  

 Appendix B 

[*****] 

  
  

PAGE 5 OF 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]